As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Jerry Hughes has selected topical, interesting papers for your perusal that also include interesting articles from the emerging economic regions and publications on COVID-19 and CML.

Read Professor Hughes' CML publications of the month: September 2021

Clinical papers

• Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: who can benefit the most?
  Efficace F and Baccarani M. J Natl Cancer Inst, September 2021 (epub ahead of print) - open access publication
• Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors
  Schoenbeck KL et al. J Natl Cancer Inst, September 2021 (epub ahead of print)
• Chronic myeloid leukemia: Modern therapies, current challenges and future directions
  Osman AEG and Deininger MW. Blood Rev, September 2021
• Long-term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic-phase treated outside clinical trials: a real-life cohort observational study
  Stagno F et al. Acta Oncol, September 2021 (epub ahead of print)
• Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: is there a real benefit?
  Canet J et al. Cancer Med, September 2021 (epub ahead of print) – open access publication
• Current evidence of the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs
  Erçaliskan A et al. Blood Adv, September 2021 - open access publication
• How I treat chronic phase chronic myelogenous leukemia
  Berman E et al. Blood, September 2021 (epub ahead of print)

Scientific papers

• Genetic heterogeneity in chronic myeloid leukemia: How clonal hematopoiesis and clonal evolution may influence prognosis, treatment outcomes, and risk of cardiovascular events
  Sant’Antonio E et al. Clin Lymphoma Myeloma Leuk, September 2021
• Granulocyt and monocytic myeloid-derived suppressor cells are functionally and prognostically different in patients with chronic myeloid leukemia
  Ahn A et al. Ann Lab Med, September 2021 – open access publication
• Association of creatine elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study
  Bankar A and Lipton LH. Leuk Lymphoma, September 2021 (epub ahead of print)
• Intracellular delivery of anti-BCR-ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells
  Jiang G et al. J Hematol Oncol, September 2021 – open access publication
• BCR-ABL1 transcript doubling time as a predictor for treatment free remission after imatinib discontinuation in chronic myeloid leukemia
  Kim DDH et al. Br J Hematol, September 2021 (epub ahead of print)

Pediatric papers

• Chronic myeloid leukemia in children: immune function and vaccinations
  Suttorp M et al. J Clin Med, September 2021 – open access publication

COVID-19 papers

COVID-19 and CML

• The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population
  Bonifacio M et al. Cancer Med, September 2021 – open access publication

COVID-19 and haematological malignancies

• Clinical profile and outcomes of COVID-19 in haematological malignancies: experience from tertiary care centre in India
  Gupta A et al. Ann Hematol, September 2021 (epub ahead of print) - open access publication